Lexington, Massachusetts-based Thea Pharma US has landed $4.0M in pre-seed funding, signaling fresh capital for its established portfolio of ophthalmic treatments. The U.S. subsidiary of Théa, founded in 2019, operates with a focus on the American market, aiming to deliver uncompromising eye care.
The company's offerings include seven FDA-regulated products such as Zioptan®, AcellFX™, and IYUZEH™, alongside iVIZIA dry-eye drops and eyelid hygiene solutions. This pre-seed round provides a boost for a firm already active with a range of approved products.















